AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo

Data ReadoutpositiveRINVOQPositive

AI Analysis

Summary

AbbVie presented long-term data from Phase 3 Viti-Up-1 and Viti-Up-2 studies demonstrating continued repigmentation with RINVOQ (upadacitinib) in non-segmental vitiligo patients. RINVOQ is the first and only systemic medication approved in the EU for this indication in eligible adult and adolescent patients.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Long-term data from Phase 3 Viti-Up-1 and Viti-Up-2 studies showing continued repigmentation in non-segmental vitiligo patients continuing RINVOQ

Importance:6/10

Sentiment:

0.70

dermatologyautoimmuneEU approvallong-term datasystemic therapy

Related Companies

$ABBV

Read the original article

Published by PR Newswire Biotech on October 1, 2026 2:00 PM

Read Original